The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase 1 trial of a novel, first-in-class G protein-coupled estrogen receptor (GPER) agonist, LNS8801, in patients with advanced or recurrent treatment-refractory solid malignancies.
 
Carolyn Muller
Research Funding - AstraZeneca (Inst); Genmab (Inst); Immunogen (Inst); Linnaeus Therapeutics (Inst); Pfizer (Inst); Roche/Genentech (Inst); TapImmune Inc. (Inst); VBL Therapeutics (Inst)
Patents, Royalties, Other Intellectual Property - Have a pending patent on the cancer use for R-ketorolac - not yet its own new drug. (Inst)
Other Relationship - NCI
 
Ursa Abigail Brown-Glaberman
Consulting or Advisory Role - Biotheranostics; Eisai; Novartis; Seagen; Taiho Oncology
Research Funding - Seagen (Inst)
 
Marya F. Chaney
Employment - Merck
Stock and Other Ownership Interests - Merck
Travel, Accommodations, Expenses - Merck
 
Tina Garyantes
Employment - Linnaeus Therapeutics
Stock and Other Ownership Interests - Linnaeus Therapeutics
Patents, Royalties, Other Intellectual Property - Linnaeus Therapeutics
 
Patricia LoRusso
Honoraria - Five Prime Therapeutics
Consulting or Advisory Role - Abbvie; ABL Bio; Agenus; Agios; Astellas Pharma; AstraZeneca; Bayer; Black Diamond Therapeutics; Cybrexa Therapeutics; CytomX Therapeutics; EMD Serono; Five Prime Therapeutics; Genentech; Genmab; GlaxoSmithKline; Halozyme; I-Mab; ImmunoMet; IQvia; Kineta; Kyowa Kirin International; Macrogenics; Molecular Templates; Molecular Templates; Pfizer; QED Therapeutics; Roche/Genentech; Salarius Pharmaceuticals; Shattuck Labs; Silverback Therapeutics; SK Life Sciences; Sotio; ST Cube; Takeda; Trial to Reduce IDDM in the Genetically at Risk (TRIGR); TYME; Zentalis
Research Funding - Genentech (Inst)
Travel, Accommodations, Expenses - Genentech
 
Jennifer Leigh McQuade
Honoraria - Merck
Consulting or Advisory Role - Bristol Myer Squibb; Roche Pharma AG
Travel, Accommodations, Expenses - Merck
 
Alain C. Mita
Speakers' Bureau - Genentech
 
Monica M. Mita
Research Funding - Seagen (Inst)
 
Christopher Natale
Employment - Linnaeus Therapeutics
Stock and Other Ownership Interests - Linnaeus Therapeutics
Patents, Royalties, Other Intellectual Property - Linnaeus Therapeutics
 
Marlana Orloff
Consulting or Advisory Role - Immunocore
Speakers' Bureau - Bristol-Myers Squibb
Research Funding - Bristol-Myers Squibb (Inst); Delcath Systems (Inst); IDEAYA Biosciences (Inst); IDEAYA Biosciences (Inst); Immunocore (Inst); Linnaeus Therapeutics (Inst); Plexxikon (Inst)
 
Kyriakos P. Papadopoulos
Consulting or Advisory Role - Basilea; Turning Point Therapeutics
Research Funding - 3D Medicines (Inst); Abbvie (Inst); ADC Therapeutics (Inst); Amgen (Inst); Anheart Therapeutics (Inst); Bayer (Inst); Calithera Biosciences (Inst); Daiichi Sankyo (Inst); EMD Serono (Inst); F-star (Inst); Incyte (Inst); Jounce Therapeutics (Inst); Lilly (Inst); Linnaeus Therapeutics (Inst); MabSpace Biosciences (Inst); MedImmune (Inst); Merck (Inst); Mersana (Inst); Mirati Therapeutics (Inst); Peloton Therapeutics (Inst); Pfizer (Inst); Regeneron (Inst); Syros Pharmaceuticals (Inst); Tempest Therapeutics (Inst); Treadwell Therapeutics (Inst)
 
Takami Sato
Consulting or Advisory Role - Castle Biosciences; Immunocore
Research Funding - Immunocore (Inst); Verastem (Inst)
Travel, Accommodations, Expenses - Castle Biosciences
 
Emrullah Yilmaz
No Relationships to Disclose
 
Jordi Rodon
Consulting or Advisory Role - Bayer; Certara Inc; Ellipses Pharma; iOnctura; Kelun; Lilly; Merck Sharp & Dohme; Molecular Partners; Novartis; NovellusDx; Orion; Peptomyc; Pfizer; Roche; SERVIER; Spectrum Pharmaceuticals
Research Funding - Bayer Health (Inst); BioAtla (Inst); Blueprint Medicines (Inst); CytomX Therapeutics (Inst); Genmab (Inst); GlaxoSmithKline (Inst); Ipsen (Inst); Kelun (Inst); Novartis (Inst); Pfizer (Inst); Spectrum Pharmaceuticals (Inst); Symphogen (Inst); Takeda/Millennium (Inst); Tocagen (Inst)
Travel, Accommodations, Expenses - Bayer; Janssen; Kelun; Merck Sharp & Dohme; Molecular Partners
Other Relationship - GlaxoSmithKline